Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 23;2013(8):CD008588.
doi: 10.1002/14651858.CD008588.pub2.

Chemotherapy for thymic carcinoma and advanced thymoma in adults

Mao Ling Wei  1 , Deying Kang, Lijia Gu, Meng Qiu, Liao Zhengyin, Yanming Mu
Affiliations

Chemotherapy for thymic carcinoma and advanced thymoma in adults

Mao Ling Wei et al. Cochrane Database Syst Rev. .

Abstract

Background: Thymic carcinoma or advanced thymoma is a rare cancer of the thymus gland that tends to be aggressive and infiltrate neighbouring organs, making total resection very difficult. Induction or adjuvant chemotherapy, or both, are often used in a multimodality approach to treat people affected by this condition, but the effectiveness of chemotherapy for thymic carcinoma or advanced thymoma remains uncertain.

Objectives: To assess the role of chemotherapy in adults with thymic carcinoma or advanced thymoma.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2012, Issue 7), MEDLINE (accessed via Ovid from 1966 to July 2012), EMBASE (accessed via Ovid, from 1980 to July 2012), Latin American and Caribbean Literature on Health Sciences (LILACS), the Chinese Biological Medicine Database (CBM, 1978 to July 2012), China National Knowledge Infrastructure (CNKI, 1980 to July 2012) and the Chinese scientific periodical database VIP Information (VIP, 1989 to July 2012). There was no language restriction in searching for studies.

Selection criteria: We planned to include randomised controlled trials (RCTs) of trials using chemotherapy (either single-agent or combination chemotherapy plus surgery, radiotherapy or not) for thymic carcinoma and/or advanced thymoma. We planned to include all adults (aged 18 years and over) diagnosed with thymic carcinoma and/or with Masaoka stage III or IV thymic tumours. The intended primary outcomes were overall survival (OS) and progression-free survival (PFS).

Data collection and analysis: Two review authors independently evaluated the search results according to the inclusion and exclusion criteria. There were no studies identified for inclusion and therefore no data extraction was completed.

Main results: No RCTs were eligible for inclusion in this review. We report details of excluded prospective studies in an additional table and try to provide some useful evidence regarding current practice.

Authors' conclusions: There were no RCTs eligible for inclusion in this review. In current practice the most common regimen for adult patients with thymic carcinoma or advanced thymoma is cisplatin-based chemotherapy. Considering the condition is rare, it is suggested that an international group is set up to organise and evaluate prospective collection of data from cohorts of patients to inform current clinical practice.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Searching flow diagram
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD008588

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies excluded from this review

Bonomi 1993 {published data only}
    1. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. American Journal of Clinical Oncology 1993;16(4):342-5. - PubMed
Bretti 2004 {published data only}
    1. Bretti S, Berruti A, Loddo C, Sperone P, Casadio C, Tessa M, et al. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer 2004;44(1):69-77. - PubMed
Cardillo 2010 {published data only}
    1. Cardillo G, Carleo F, Giunti R, Lopergolo MG, Salvadori L, De Massimi AR, et al. Predictors of survival in patients with locally advanced thymoma (Masaoka stage III and IVa). European Journal of Cardio-thoracic Surgery 2010;37:819-23. - PubMed
Cowen 1995 {published data only}
    1. Cowen D, Richaud P, Mornex F, Bachelot T, Jung GM, Mirabel X, et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer. Radiotherapy and Oncology 1995;34(1):9-16. - PubMed
Daniele 2003 {published data only}
    1. Daniele O, Fornasiero A. Ifosfamide in thymic neoplasms. Oncology 2003;65 Suppl 2:44-5. - PubMed
Evans 2005 {published data only}
    1. Evans TL, Lynch TJ. Role of chemotherapy in the management of advanced thymic tumors. Seminars in Thoracic and Cardiovascular Surgery 2005;17:41-50. - PubMed
Falkson 2009 {published data only}
    1. Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: a systematic review and practice guideline. Journal of Thoracic Oncology 2009;4(7):911-9. - PubMed
Fan 2008 {published data only}
    1. Fan RT, Wang JM, Zhang HZ, Guo YN, Gu H. Clinical analysis of 45 patients with thymic carcinoma. Chinese Journal of Clinical Oncology 2008;35(9):488-93.
Fornasiero 1990 {published data only}
    1. Fornasiero A, Daniele O, Ghiotto C, Sartori F, Rea F, Piazza M, et al. Chemotherapy of invasive thymoma. Journal of Clinical Oncology 1990;8(8):1419-23. - PubMed
Fornasiero 1991 {published data only}
    1. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabró F, et al. Chemotherapy for invasive thymoma. A 13-year experience. Cancer 1991;68(1):30-3. - PubMed
Fujimura 1987 {published data only}
    1. Fujimura ST, Kondo T, Handa M, Shiraishi Y, Tamahashi N, Nakada T. Results of surgical treatment for thymoma based on 66 patients. Journal of Thoracic and Cardiovascular Surgery 1987;93(5):708-14. - PubMed
Giaccone 1996 {published data only}
    1. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, Zandwijk NV. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Journal of Clinical Oncology 1996;14(3):814-20. - PubMed
Giaccone 2000 {published data only}
    1. Giaccone G. Treatment of thymoma and thymic carcinoma. Annals of Oncology 2000;11(Suppl 3):245-6. - PubMed
Giaccone 2006 {published data only}
    1. Giaccone G, Wilmink H, Paul MA, Valk P. Systemic treatment of malignant thymoma: a decade experience at a single institution. American Journal of Clinical Oncology 2006;29:336-44. - PubMed
Girard 2009 {published data only}
    1. Girard N, Mornex F, Van Houtte P, Cordier JF, Schil P. Thymoma: A focus on current therapeutic management. Journal of Thoracic Oncology 2009;4(1):119-26. - PubMed
Grassin 2010 {published data only}
    1. Grassin F, Paleiron N, André M, Caliandro R, Bretel JJ, Terrier P, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. Journal of Thoracic Oncology 2010;5(6):893-7. - PubMed
Gripp 1998 {published data only}
    1. Gripp S, Hilgers K, Wurm R, Schmitt G. Thymoma: prognostic factors and treatment outcomes. Cancer 1998;83(8):1495-503. - PubMed
Huang 2008 {published data only}
    1. Huang J, Riely GJ, Rosenzweig KE, Rusch VW. Multimodality therapy for locally advanced thymomas: state of the art or investigational therapy? Annals of Thoracic Surgery 2008;85(2):365-7. - PubMed
Huang 2009 {published data only}
    1. Huang J, Rizk NP, Travis WD, Riely GJ, Park BJ, Bains MS, et al. Comparison of patterns of relapse in thymic carcinoma and thymoma. Journal of Thoracic and Cardiovascular Surgery 2009;138(1):26-31. - PMC - PubMed
Kim 2004 {published data only}
    1. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44(3):369-79. - PubMed
Kim 2008 {published data only}
    1. Kim BK, Cho BC, Choi HJ, Sohn JH, Park MS, Chang J, et al. A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features. Oncology Reports 2008;19(6):1525-31. - PubMed
Koizumi 2002 {published data only}
    1. Koizumi T, Takabayashi Y, Yamagishi S, Tsushima K, Takamizawa A, Tsukadaira A, et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). American Journal of Clinical Oncology 2002;25(3):266-8. - PubMed
Kong 2005 {published data only}
    1. Kong DS, Lee JI, Nam DH, Park K, Suh YL. Cerebral involvement of metastatic thymic carcinoma. Journal of Neuro-Oncology 2005;75(2):143-7. - PubMed
Kunitoh 2009 {published data only}
    1. Kunitoh H, Tamura T, Shibata T, Nakagawa K, Takeda K, Nishiwaki Y, et al, JCOG Lung Cancer Study Group, Tokyo, Japan. A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: Report of a Japan Clinical Oncology Group trial (JCOG 9605). British Journal of Cancer 2009;101(9):1549-54. - PMC - PubMed
Kunitoh 2010 {published data only}
    1. Kunitoh H, Tamura T, Shibata T, Takeda K, Katakami N, Nakagawa K, et al. A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606). British Journal of Cancer 2010;103:6-11. - PMC - PubMed
Kurup 2004 {published data only}
    1. Kurup A, Loehrer PJ Sr. Thymoma and thymic carcinoma: therapeutic approaches. Clinical Lung Cancer 2004;6(1):28-32. - PubMed
Lee 2009 {published data only}
    1. Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Chung KY. Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution. European Journal of Cardio-Thoracic Surgery 2009;36(1):159-63. - PubMed
Loehrer 1994 {published data only}
    1. Loehrer PJ Sr, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. Journal of Clinical Oncology 1994;12(6):1164-8. - PubMed
Loehrer 2001 {published data only}
    1. Loehrer PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91(11):2010-5. - PubMed
Loehrer 2004 {published data only}
    1. Loehrer PJ, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group phase II trial. Journal of Clinical Oncology 2004;22(2):293-9. - PubMed
Lucchi 2005 {published data only}
    1. Lucchi M, Ambrogi MC, Duranti L, Basolo F, Fontanini G, Angeletti CA, et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Annals of Thoracic Surgery 2005;79(6):1840-4. - PubMed
Lucchi 2006 {published data only}
    1. Lucchi M, Melfi F, Dini P, Basolo F, Viti A, Givigliano F, et al. Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. Journal of Thoracic Oncology 2006;1(4):308-13. - PubMed
Luo 2004 {published data only}
    1. Luo QQ, Zhou YZ, Chen WH, Huang G, Yang J, Zhao XQ, et al. The reduction chemotherapy to the gigantic thymic malignant tumor before surgical treatment. Chinese Journal of Clinical Oncology 2004;31(2):92-4.
Myojin 2000 {published data only}
    1. Myojin M, Choi NC, Wright CD, Wain JC, Harris N, Hug EB, et al. Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study. International Journal of Radiation Oncology, Biology, Physics 2000;46(4):927-33. - PubMed
Oberg 2009 {published data only}
    1. Oberg K, Hellman P, Kwekkeboom D, Jelic S, ESMO Guidelines Working Group. Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up. Annals of Oncology 2009;20(Suppl 4):147-9. - PubMed
Palmieri 2010 {published data only}
    1. Palmieri G, Merola G, Federico P, Petillo L, Marino M, Ceribelli, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Annals of Oncology 2010;21:1168-72. - PubMed
Rajan 2008 {published data only}
    1. Rajan A, Giaccone G. Treatment of advanced thymoma and thymic carcinoma. Current Treatment Options in Oncology 2008;9(4-6):277-87. - PMC - PubMed
Rajan 2011 {published data only}
    1. Rajan A, Giaccone G. Chemotherapy for thymic tumors: induction, consolidation, palliation. Thoracic Surgery Clinics 2011;21(1):107-14. - PubMed
Rea 2011 {published data only}
    1. Rea F, Marulli G, Di Chiara F, Schiavon M, Perissinotto E, Breda C, et al. Multidisciplinary approach for advanced stage thymic tumors: long-term outcome. Lung Cancer 2011;72(1):68-72. - PubMed
Shin 1998 {published data only}
    1. Shin DM, Walsh GL, Komaki R, Putnam JB, Nesbitt J, Ro JY, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. Annals of Internal Medicine 1998;129(2):100-4. - PubMed
Ströbel 2004 {published data only}
    1. Ströbel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. Journal of Clinical Oncology 2004;22(8):1501-9. - PubMed
Venuta 1997 {published data only}
    1. Venuta F, Rendina EA, Longo F, Giacomo TD, Anile M, Mercadante E, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. Annals of Thoracic Surgery 2003;76:1866-72. - PubMed
Venuta 2003 {published data only}
    1. Venuta F, Rendina EA, Longo F, De Giacomo T, Anile M, Mercadante E, et al. Long- term outcome after multimodality treatment for stage III thymic tumors. Annals of Thoracic Surgery 2003;76(6):1866-72. - PubMed
White 1990 {published data only}
    1. White L, Grossmann R, Tobias VH. Effective chemotherapy for invasive thymoma and thymic carcinoma: review of the literature. Cancer Journal 1990;3(2):110-2.
Wright 2005 {published data only}
    1. Wright CD, Wain JC, Wong DR, Donahue DM, Gaissert HA, Grillo HC, et al. Predictors of recurrence in thymic tumors: Importance of invasion, World Health Organization histology, and size. Journal of Thoracic and Cardiovascular Surgery 2005;130(5):1413-21. - PubMed
Xu 2009 {published data only}
    1. Xu JP, Zhang XR, Hao XZ, Li JL. Gemcitabine combined with cisplatin/carboplatin in treatment of advanced thymic carcinoma. World Clinical Drugs 2009;30(6):358-60.
Yano 2005 {published data only}
    1. Yano M, Fujii Y. Thymoma in elderly patients. Japanese Journal of Thoracic Surgery 2005;58(8 Suppl):739-44. - PubMed
Yokoi 2007 {published data only}
    1. Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. Journal of Thoracic Oncology 2007;2(1):73-8. - PubMed
Zhu 2009 {published data only}
    1. Zhu WY, Han JQ. 3 Dimensional Conformal Radiotherapy Combined with Chemotherapy for Thymoma [Thesis]. Shandong University, 2009.

Additional references

Chung 2000
    1. Chung DA. Thymic carcinoma - analysis of nineteen clinicopathological studies. Thoracic and Cardiovascular Surgeon 2000;48:114-9. - PubMed
CTCAE 2006
    1. Common Terminology Criteria for Adverse Events (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/... 9 August 2006. - PubMed
Eisenhauer 2009
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009;45:228-47. - PubMed
Eng 2004
    1. Eng TY, Fuller CD, Jagirdar J, Bains Y, Thomas CR. Thymic carcinoma: state of the art review. International Journal of Radiation Oncology, Biology, Physics 2004;59(3):654-64. - PubMed
Falkson 2008
    1. Falkson C, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak D, et al. The management of thymoma: guideline recommendations. Toronto (ON): Cancer Care Ontario Program in Evidence-based Care 2008 Sep 26. 41 p;(Evidence-based series; no. 7-11).
Geffen 2001
    1. Geffen DB, Benharroch D, Yellin A, Ariad S, Or R, Cohen Y. Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation [case report]. American Journal of Clinical Oncology 2001;24(6):566-9. - PubMed
Giaccone 2005
    1. Giuseppe G. Treatment of malignant thymoma. Current Opinion in Oncology 2005;17:140-6. - PubMed
Hernandez‐Ilizaliturri 2004
    1. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, Connolly G, Debb G, Ramnath N. Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience. American Journal of Clinical Oncology 2004;27(2):127. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org..
Hsu 1994
    1. Hsu CP. Thymic carcinoma. Ten year's experience in twenty patients. Journal of Thoracic and Cardiovascular Surgery 1994;107:615-20. - PubMed
Ji 2006
    1. Ji W, Feng QF, Zhou ZM, Wang M, Chen DF, Zhang HX, et al. Analysis of treatment and prognosis of 73 thymic carcinoma patients. Chinese Journal of Radiation Oncology 2006;15(2):97-100.
Kitami 2001
    1. Kitami A, Suzuki T, Kamio Y, Suzuki S. Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature. Japanese Journal of Clinical Oncology 2001;31(12):601-4. - PubMed
Kondo 2003
    1. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Annals of Thoracic Surgery 2003;76:878-84. - PubMed
Lin 2005
    1. Lin JT, Wei-Shu W, Yen CC, Liu JH, Chen PM, Chiou TJ. Stage IV thymic carcinoma: a study of 20 patients. American Journal of the Medical Sciences 2005;330(4):172-5. - PubMed
Liu 2002
    1. Liu HC, Hsu WH, Chen YJ, Chan YJ, Wu YC, Huang BS, et al. Primary thymic carcinoma. Annals of Thoracic Surgery 2002;73:1076-81. - PubMed
Masaoka 1981
    1. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymoma with special reference to their clinical stages. Cancer 1981;48:2485-92. - PubMed
Nakamura 2000
    1. Nakamura Y, Kunitoh H, Kubota K. Platinum-based chemotherapy with or without thoracic radiation therapy in patients with thymic carcinoma. Japanese Journal of Clinical Oncology 2000;30(9):385-8. - PubMed
Rosai 1999
    1. Rosai J. Histological typing of tumors of the thymus. 2nd edition. New York: Springer-Verlag, 1999.
Tetsuo 2004
    1. Tetsuo N, Yoshio T, Keiko H, Hiroyuki K, Masumi N, Hiroyuki H, et al. The role of radiotherapy for thymic carcinoma. Japanese Journal of Clinical Oncology 2004;34(12):722-6. - PubMed
Travis 2004
    1. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004.
Weide 1993
    1. Weide L, Ulbright T, Loehrer P, Williams S. Thymic carcinoma: a distinct clinical entity responsive to chemotherapy. Cancer 1993;71(4):1219-23. - PubMed
Yano 2008
    1. Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S, et al. Thymic carcinoma: 30 cases at a single institution. Journal of Thoracic Oncology 2008;3(3):265-9. - PubMed
Zhang 2007
    1. Zhang J, Huang C, Zhu K. Analysis of clinical characters and prognosis of 32 thymic carcinoma. Jiangxi Yiyao 2007;42(11):994-5.

Publication types

Substances

LinkOut - more resources